4.7 Article

Impact of New Antifungal Breakpoints on Antifungal Resistance in Candida Species

期刊

JOURNAL OF CLINICAL MICROBIOLOGY
卷 52, 期 3, 页码 994-997

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.03044-13

关键词

-

资金

  1. Pfizer
  2. Merck
  3. Basilea
  4. Astellas
  5. Viamet
  6. bioMerieux
  7. Medicis

向作者/读者索取更多资源

We reviewed our antifungal susceptibility data for micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resistance rates determined by the previous and recently revised CLSI antifungal breakpoints. With the new breakpoints, resistance was significantly increased for micafungin (from 0.8% to 7.6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabrata. Resistance was also increased for fluconazole against Candida albicans (from 2.1% to 5.7%).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据